Collin M Blakely, MD
Medical Oncology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Offices
- 2
- Since medical school
- 19 years
- Perelman School of Med at the University of Pennsylvania, 2007
Offices
2 locations · University of California San Francisco · UCSF Medical Group Business Services
Hospitals listed: Mills-Peninsula Medical Center · UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Blakely’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A106689 · Current
Licensed to practise in California · since 2009 · expires 2028-06-30 · University of Pennsylvania School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Medical Oncology
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$33,200
Medicare paid this office $33,200 for 80 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 53 | $21,305 | $125 |
| Return visit (30+ min) | 36 | $3,941 | $80 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 72 | $3,149 | $15 |
| New patient visit (60+ min) | 13 | $1,656 | $127 |
Who their Medicare patients are
80 Original Medicare patients in 2024. Average age 74 · Women 74% · Also on Medicaid 16% · Health risk score 2.68. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: Cancer 75% · High blood pressure 61% · Coronary heart disease 24% · COPD 21% · Depression 21% · Diabetes 19% · Chronic kidney disease 16% · Atrial fibrillation 15%.
The office billed $226,825, Medicare allowed $43,605 and paid $33,200; for 1,016 services of 22 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 80 | 1,016 | 74 | 2.68 | $226,825 | $33,200 |
| 2023 | 92 | 856 | 73 | 2.61 | $416,706 | $40,352 |
| 2022 | 92 | 316 | 72 | 2.09 | $196,337 | $30,887 |
| 2021 | 96 | 295 | 73 | 2.51 | $195,014 | $30,991 |
| 2020 | 78 | 258 | 72 | 2.45 | $172,005 | $21,750 |
| 2019 | 94 | 268 | 72 | 2.44 | $205,230 | $25,838 |
| 2018 | 102 | 298 | 72 | 2.30 | $212,424 | $27,122 |
| 2017 | 106 | 344 | 72 | 2.41 | $236,573 | $32,491 |
| 2016 | 99 | 386 | 73 | 2.35 | $239,362 | $33,815 |
| 2015 | 70 | 266 | 72 | 2.08 | $165,094 | $23,133 |
| 2014 | 41 | 171 | 74 | 2.04 | $111,761 | $15,663 |
| 2013 | 24 | 42 | 75 | 1.32 | $29,206 | $4,228 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Long return visit (40+ min) | 42 | $16,826 | $125 |
| Return visit (30+ min) | 58 | $8,543 | $81 |
| New patient visit (60+ min) | 21 | $3,261 | $155 |
2022: 3 services
| Long return visit (40+ min) | 41 | $13,155 | $122 |
| Return visit (30+ min) | 65 | $9,901 | $81 |
| New patient visit (60+ min) | 14 | $2,039 | $146 |
2021: 4 services
| Long return visit (40+ min) | 49 | $13,942 | $127 |
| Return visit (30+ min) | 54 | $9,729 | $86 |
| New patient visit (60+ min) | 21 | $3,493 | $166 |
| Short return visit (20+ min) | 23 | $1,304 | $54 |
2020: 2 services
| Long return visit (40+ min) | 51 | $12,485 | $95 |
| Return visit (30+ min) | 51 | $6,174 | $69 |
2019: 2 services
| Long return visit (40+ min) | 82 | $22,415 | $97 |
| New patient visit (60+ min) | 18 | $2,576 | $143 |
2018: 3 services
| Long return visit (40+ min) | 86 | $20,242 | $92 |
| Return visit (30+ min) | 26 | $3,427 | $66 |
| New patient visit (60+ min) | 20 | $2,980 | $149 |
2017: 4 services
| Long return visit (40+ min) | 85 | $24,131 | $98 |
| New patient visit (60+ min) | 28 | $3,563 | $127 |
| Return visit (30+ min) | 36 | $3,226 | $63 |
| New patient visit (45+ min) | 12 | $1,268 | $106 |
2016: 4 services
| Long return visit (40+ min) | 43 | $15,947 | $99 |
| Return visit (30+ min) | 49 | $8,579 | $68 |
| New patient visit (60+ min) | 35 | $5,256 | $150 |
| Short return visit (20+ min) | 27 | $1,832 | $44 |
2015: 5 services
| Long return visit (40+ min) | 35 | $10,712 | $97 |
| Return visit (30+ min) | 37 | $5,556 | $69 |
| New patient visit (60+ min) | 34 | $5,080 | $149 |
| Short return visit (20+ min) | 16 | $1,043 | $45 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $99 | $8 |
2014: 3 services
| Long return visit (40+ min) | 24 | $10,575 | $99 |
| New patient visit (60+ min) | 23 | $3,066 | $133 |
| Return visit (30+ min) | 17 | $1,557 | $62 |
2013: 2 services
| New patient visit (60+ min) | 13 | $1,875 | $144 |
| Long return visit (40+ min) | 11 | $1,727 | $91 |
Drugs they prescribed that Part D paid
$2,954,344
Pharmacies billed $2,954,344 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
70 generic and 181 brand-name prescriptions · $2,954,344 in drug cost · 17 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tagrisso | 102 | $1,797,694 | $17,624 |
| Lorbrena | 30 | $659,524 | $21,984 |
| Xalkori | 12 | $269,365 | $22,447 |
| Eliquis | 20 | $11,712 | $586 |
| Dexamethasone | 13 | $486 | $37 |
See all 6 drugs
| Tagrisso | 102 | $1,797,694 | $17,624 |
| Lorbrena | 30 | $659,524 | $21,984 |
| Xalkori | 12 | $269,365 | $22,447 |
| Eliquis | 20 | $11,712 | $586 |
| Dexamethasone | 13 | $486 | $37 |
| Furosemide | 15 | $44 | $3 |
Year by year
| 2024 | 251 | 38 | None | 72% | $2,954,344 |
| 2023 | 270 | 37 | 0% (0) | 76% | $3,112,850 |
| 2022 | 247 | 42 | None | 75% | $2,782,476 |
| 2021 | 215 | 37 | None | 63% | $1,772,429 |
| 2020 | 153 | 28 | None | 58% | $973,642 |
| 2019 | 162 | 34 | None | 41% | $638,809 |
| 2018 | 227 | 37 | None | 34% | $624,692 |
| 2017 | 206 | 34 | None | 47% | $595,682 |
| 2016 | 243 | 36 | None | 43% | $765,759 |
| 2015 | 233 | 36 | None | None | $343,180 |
| 2014 | 151 | 18 | 13% (19) | 30% | $229,124 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Tagrisso | 136 | $2,265,822 | $16,660 |
| Lorbrena | 16 | $320,359 | $20,022 |
| Xalkori | 12 | $254,203 | $21,184 |
| Eliquis | 27 | $16,581 | $614 |
| Erlotinib | 15 | $14,438 | $963 |
| Ondansetron | 11 | $122 | $11 |
2022: 5 drugs
| Tagrisso | 119 | $1,904,070 | $16,001 |
| Lorbrena | 24 | $443,081 | $18,462 |
| Xalkori | 14 | $273,276 | $19,520 |
| Lamivudine Hbv | 11 | $765 | $70 |
| Amlodipine Besylate | 12 | $135 | $11 |
2021: 6 drugs
| Tagrisso | 86 | $1,367,506 | $15,901 |
| Lorbrena | 14 | $256,821 | $18,344 |
| Eliquis | 16 | $11,433 | $715 |
| Ondansetron | 16 | $582 | $36 |
| Dexamethasone | 11 | $242 | $22 |
| Prochlorperazine Maleate | 18 | $183 | $10 |
2020: 4 drugs
| Tagrisso | 55 | $876,727 | $15,940 |
| Eliquis | 12 | $5,479 | $457 |
| Clindamycin Phosphate | 15 | $230 | $15 |
| Furosemide | 11 | $20 | $2 |
2019: 6 drugs
| Tagrisso | 28 | $435,730 | $15,562 |
| Lorbrena | 12 | $100,193 | $8,349 |
| Dexamethasone | 12 | $421 | $35 |
| Ondansetron | 19 | $356 | $19 |
| Prochlorperazine Maleate | 16 | $118 | $7 |
| Lorazepam | 16 | $50 | $3 |
2018: 7 drugs
| Tagrisso | 26 | $396,711 | $15,258 |
| Tarceva | 21 | $160,723 | $7,653 |
| Ondansetron | 24 | $714 | $30 |
| Dexamethasone | 19 | $629 | $33 |
| Prochlorperazine Maleate | 34 | $233 | $7 |
| Levothyroxine | 12 | $163 | $14 |
| Lorazepam | 24 | $162 | $7 |
2017: 6 drugs
| Tarceva | 47 | $302,026 | $6,426 |
| Tagrisso | 17 | $235,912 | $13,877 |
| Xarelto | 16 | $6,536 | $409 |
| Ondansetron | 30 | $386 | $13 |
| Dexamethasone | 14 | $210 | $15 |
| Prochlorperazine Maleate | 21 | $137 | $7 |
2016: 8 drugs
| Tagrisso | 24 | $331,741 | $13,823 |
| Tarceva | 42 | $286,493 | $6,821 |
| Xarelto | 12 | $4,471 | $373 |
| Prochlorperazine Maleate | 27 | $207 | $8 |
| Ondansetron | 17 | $165 | $10 |
| Dexamethasone | 13 | $134 | $10 |
| Lorazepam | 15 | $100 | $7 |
| Metformin Hcl Er | 11 | $27 | $2 |
2015: 7 drugs
| Tarceva | 35 | $228,759 | $6,536 |
| Gilotrif | 11 | $74,990 | $6,817 |
| Clindamycin Phosphate | 11 | $693 | $63 |
| Ondansetron | 19 | $499 | $26 |
| Dexamethasone | 27 | $263 | $10 |
| Prochlorperazine Maleate | 16 | $109 | $7 |
| Lorazepam | 20 | $99 | $5 |
2014: 4 drugs
| Tarceva | 27 | $203,864 | $7,551 |
| Clindamycin Phosphate | 16 | $1,098 | $69 |
| Lidocaine Hcl Viscous | 13 | $120 | $9 |
| Lorazepam | 17 | $85 | $5 |
Money from drug and device companies
$4,952 in 2025
| 2025 | 4 | 4 | $4,890 | $4,952 |
| 2024 | 6 | 13 | $11,625 | $13,044 |
| 2023 | 4 | 7 | $5,350 | $23,625 |
| 2022 | 3 | 3 | $3,628 | $22,378 |
| 2021 | 1 | 1 | $560 | $560 |
| 2020 | 5 | 9 | $10,525 | $10,640 |
| 2019 | 6 | 16 | $5,323 | $5,512 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pfizer | Lorbrena | $2,520 | 1 payment
|
| Janssen Biotech | Rybrevant | $1,670 | 1 payment
|
| Taiho Oncology | None | $700 | 1 payment
|
| Daiichi Sankyo | Datroway | $62 | 1 payment
|
See all 4 published payments
| Janssen Biotech | Consulting · 2025-11-06 | Rybrevant | $1,670 |
| Pfizer | Consulting · 2025-06-20 | Lorbrena | $2,520 |
| Taiho Oncology | Paid to speak or teach · 2025-04-30 | None | $700 |
| Daiichi Sankyo | Education · 2025-02-07 | Datroway | $62 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $13,044
| Taiho Oncology | None | $5,485 | 7 payments
|
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $2,700 | 1 payment
|
| Janssen Scientific Affairs | None | $1,875 | 1 payment
|
| Pfizer | Lorbrena | $1,709 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | None | $650 | 1 payment
|
| Genentech | None | $625 | 1 payment
|
2023: $23,625
| Genentech | None | $18,182 | 1 payment
|
| Gilead Sciences | Trodelvy | $2,713 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Vitrakvi | $1,400 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $1,330 | 2 payments
|
2022: $22,378
| Genentech | None | $18,750 | 1 payment
|
| Janssen Biotech | None | $1,860 | 1 payment
|
| Janssen Scientific Affairs | Rybrevant | $1,768 | 1 payment
|
2021: $560
| Blueprint Medicines | None | $560 | 1 payment
|
2020: $10,640
| Amgen | None | $6,325 | 4 payments
|
| Bayer HealthCare Pharmaceuticals | Vitrakvi | $2,100 | 1 payment
|
| Blueprint Medicines | None | $1,400 | 1 payment
|
| Foundation Medicine | Foundationone Liquid | $700 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | None | $115 | 1 payment
|
2019: $5,512
| F. Hoffmann-La Roche AG | Non-Covered Product | $4,360 | 9 payments
|
| Foundation Medicine | Foundationone Liquid | $963 | 3 payments
|
| Eli Lilly and | None | $148 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $26 | 1 payment
|
| Pfizer | Lorbrena | $11 | 1 payment
|
| Genentech USA | Tecentriq | $4 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · A Phase I/II Study of Capmatinib Plus Trametinib in Patients With Metastatic Met Exon 14 Skipping Mutation Positive Nsclc · 2023 | Their institution | $1,362,275 |
| AstraZeneca Pharmaceuticals LP · A Phase II Study To Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable Egfr-Mutant Non-Small Cell Lung Cancer · 2019 | Their institution | $982,464 |
| AstraZeneca Pharmaceuticals LP · A Phase II Study To Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable Egfr-Mutant Non-Small Cell Lung Cancer · 2022 | Their institution | $763,663 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase I Study of Brigatinib With Binimetinib in Advanced Alk- Or Ros1-Rearranged Non-Small Cell Lung Cancer (Nsclc) · 2021 | Their institution | $544,408 |
| Novartis Pharmaceuticals Corporation · A Phase I/II Study of Capmatinib Plus Trametinib in Patients With Metastatic Met Exon 14 Skipping Mutation Positive Nsclc · 2022 | Their institution | $385,647 |
| AstraZeneca Pharmaceuticals LP · A Phase II Study To Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable Egfr-Mutant Non-Small Cell Lung Cancer · 2021 | Their institution | $375,611 |
| AstraZeneca Pharmaceuticals LP · A Phase II Study To Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable Egfr-Mutant Non-Small Cell Lung Cancer · 2024 | Their institution | $309,655 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase I/Ib Study of Alisertib in Combination With Osimertinib in Metastatic Egfr-Mutant Lung Cancer. · 2020 | Their institution | $290,239 |
| AstraZeneca Pharmaceuticals LP · A Phase II Study To Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable Egfr-Mutant Non-Small Cell Lung Cancer · 2020 | Their institution | $284,800 |
| Novartis Pharmaceuticals Corporation · A Phase I II Study of Ceritinib Trametinib in Patients With Advanced Alk Positive Nsclc · 2019 | Their institution | $269,809 |
| Novartis Pharmaceuticals Corporation · A Phase I II Study of Ceritinib Trametinib in Patients With Advanced Alk Positive Nsclc · 2020 | Their institution | $262,984 |
| PUMA BIOTECHNOLOGY, INC. · Alisertib in Combination With Osimertinib in Metastatic Egfr Mutant Lung Cancer · 2023 | Their institution | $221,274 |
| Genentech, Inc. · Startrk 2 Rxdx 101 02 · 2019 | Their institution | $181,284 |
| Novartis Pharmaceuticals Corporation · Phase II Trial of Ceritinib in Combination With Stereotactic Ablative Radiation Sabr in Alk Rearranged Metastatic Lung Adenocarcinoma · 2021 | Their institution | $160,230 |
| PFIZER INC. · A Phase I Study of Brigatinib With Binimetinib in Advanced Alk Or Ros1rearranged Nonsmall Cell Lung Cancer Nsclc · 2022 | Their institution | $131,214 |
| AstraZeneca Pharmaceuticals LP · An Open-Label, Randomized, Multicenter, Phase 3 Study To Assess the Efficacy and Safety of Trastuzumab Deruxtecan As First-Line Treatment of Unresectable, Locally Advanced Or Metastatic Nsclc Harboring A Her2 Exon 19 Or 20 Mutation (Destiny-Lung04) · 2023 | Their institution | $129,802 |
| Genentech, Inc. · Startrk 2 Rxdx 101 02 · 2021 | Their institution | $121,336 |
| Mirati Therapeutics, Inc. · A Phase 2 Trial of Mrtx849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With Kras G12c Mutation · 2023 | Their institution | $118,262 |
| PFIZER INC. · A Phase I Study of Brigatinib With Binimetinib in Advanced Alk Or Ros1rearranged Nonsmall Cell Lung Cancer Nsclc · 2021 | Their institution | $111,936 |
| Mirati Therapeutics, Inc. · A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and A Phase 3 Trial of Adagrasib in Combination · 2024 | Their institution | $106,539 |
| Genentech, Inc. · A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divaras · 2025 | Their institution | $102,284 |
| PUMA BIOTECHNOLOGY, INC. · Alisertib in Combination With Osimertinib in Metastatic Egfr-Mutant Lung Cancer · 2024 | Their institution | $92,198 |
| Mirati Therapeutics, Inc. · A Phase 2 Trial of Mrtx849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With Kras G12c Mutation · 2025 | Their institution | $84,962 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase I Study of Brigatinib With Binimetinib in Advanced Alk- Or Ros1-Rearranged Non-Small Cell Lung Cancer (Nsclc) · 2022 | Their institution | $80,942 |
| Novartis Pharmaceuticals Corporation · A Phase I/II Study of Capmatinib Plus Trametinib in Patients With Metastatic Met Exon 14 Skipping Mutation Positive Nsclc · 2024 | Their institution | $71,024 |
| AstraZeneca Pharmaceuticals LP · A Phase II Study To Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable Egfr-Mutant Non-Small Cell Lung Cancer · 2023 | Their institution | $68,518 |
| AstraZeneca Pharmaceuticals LP · An Open-Label Window of Opportunity Trial To Evaluate the Effect of Durvalumab (D) and Tremelimumab (T) With Platinum-Based Chemotherapy (Gemcis) in Intrahepatic Cholangiocarcinoma (Icc) · 2023 | Their institution | $67,543 |
| Novartis Pharmaceuticals Corporation · A Phase I II Study of Ceritinib Trametinib in Patients With Advanced Alk Positive Nsclc · 2022 | Their institution | $64,482 |
| AstraZeneca Pharmaceuticals LP · An Open-Label, Randomized, Multicenter, Phase 3 Study To Assess the Efficacy and Safety of Trastuzumab Deruxtecan As First-Line Treatment of Unresectable, Locally Advanced Or Metastatic Nsclc Harboring A Her2 Exon 19 Or 20 Mutation (Destiny-Lung04) · 2024 | Their institution | $64,104 |
| AstraZeneca Pharmaceuticals LP · Multiarm Open Label Multicenter Phase 1b 2 Study To Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced Egfrm Nsclc · 2019 | Their institution | $57,174 |
| AstraZeneca Pharmaceuticals LP · Multiarm Open Label Multicenter Phase 1b 2 Study To Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced Egfrm Nsclc · 2020 | Their institution | $53,261 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Controlled, Multi-Centre Study of Neoadjuvant Osimertinib As Monotherapy Or in Combination With Chemotherapy Versus Soc Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable, Stages II and Iiia Non-Small Cell Lung Cancer (Neoadaura) · 2023 | Their institution | $51,749 |
| Genentech, Inc. · Startrk 2 Rxdx 101 02 · 2020 | Their institution | $51,123 |
| Novartis Pharmaceuticals Corporation · Phase II Trial of Ceritinib in Combination With Stereotactic Ablative Radiation Sabr in Alk Rearranged Metastatic Lung Adenocarcinoma · 2022 | Their institution | $45,119 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Controlled, Multi-Centre Study of Neoadjuvant Osimertinib As Monotherapy Or in Combination With Chemotherapy Versus Soc Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable, Stages II and Iiia Non-Small Cell Lung Cancer (Neoadaura) · 2022 | Their institution | $44,434 |
| Genentech, Inc. · Startrk 2 Rxdx 101 02 · 2023 | Their institution | $40,049 |
| F. Hoffmann-La Roche AG · Nautika1 Previously Lcmc4 · 2024 | Their institution | $35,588 |
| Novartis Pharmaceuticals Corporation · A Phase I II Study of Ceritinib Trametinib in Patients With Advanced Alk Positive Nsclc · 2021 | Their institution | $35,200 |
| AstraZeneca Pharmaceuticals LP · Phase III Study Non Small Cell Lung Cancer (Nsclc) Adaura2, Nct05120349, 2021-004135-89, Tagrisso · 2022 | Their institution | $34,760 |
| Novartis Pharmaceuticals Corporation · A Phase II Trial To Evaluate Trametinib in Molecular Subpopulation of Patients With Advanced Nonsmalllung Cancer · 2019 | Their institution | $33,147 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Controlled, Multi-Centre Study of Neoadjuvant Osimertinib As Monotherapy Or in Combination With Chemotherapy Versus Soc Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable, Stages II and Iiia Non-Small Cell Lung Cancer (Neoadaura) · 2024 | Their institution | $31,926 |
| Novartis Pharmaceuticals Corporation · Phase II Trial of Ceritinib in Combination With Stereotactic Ablative Radiation Sabr in Alk Rearranged Metastatic Lung Adenocarcinoma · 2019 | Their institution | $30,637 |
| Genentech, Inc. · Master A136751 Task Order Genetic and Epigenetic Resist · 2021 | Their institution | $30,000 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase I Study of Brigatinib With Binimetinib in Advanced Alk- Or Ros1-Rearranged Non-Small Cell Lung Cancer (Nsclc) · 2023 | Their institution | $29,758 |
| Mirati Therapeutics, Inc. · A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With Kras G12c Mutatio · 2025 | Their institution | $28,536 |
| Genentech, Inc. · Startrk 2 Rxdx 101 02 · 2022 | Their institution | $27,087 |
| Genentech, Inc. · Startrk 2 Rxdx 101 02 · 2024 | Their institution | $23,001 |
| Mirati Therapeutics, Inc. · 849vs1 Verastem P1/2 Adagrasib + Vs-6766 Combo · 2023 | Their institution | $20,959 |
| AstraZeneca Pharmaceuticals LP · An Open-Label, Randomized, Multicenter, Phase 3 Study To Assess the Efficacy and Safety of Trastuzumab Deruxtecan As First-Line Treatment of Unresectable, Locally Advanced Or Metastatic Nsclc Harboring A Her2 Exon 19 Or 20 Mutation (Destiny-Lung04) · 2025 | Their institution | $18,073 |
| AstraZeneca Pharmaceuticals LP · A Phase III Double-Blind Randomised Placebo-Controlled International Study To Assess the Efficacy and Safety of Adjuvant Osimertinib Versus Placebo in Participants With Egfr Mutation Positive Stage Ia2-Ia3 Non-Small Cell Lung Cancer Following Complete Tumour Resection · 2024 | Their institution | $17,921 |
| Mirati Therapeutics, Inc. · A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression on Or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy Sapphire · 2023 | Their institution | $17,363 |
| Genentech, Inc. · Nautika1 Previously Lcmc4 · 2024 | Their institution | $16,804 |
| AstraZeneca Pharmaceuticals LP · A Phase 1, 2 Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Medi4736 in Subjects With Advanced Solid Tumors · 2020 | Their institution | $15,344 |
| Spectrum Pharmaceuticals Inc. · A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer (Nsclc), Locally Advanced Or Metastatic, With Egfr Or Her2 Exon 20 Insertion Mutation (Zenith20) · 2023 | Their institution | $15,265 |
| AstraZeneca Pharmaceuticals LP · Multiarm Open Label Multicenter Phase 1b 2 Study To Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced Egfrm Nsclc · 2021 | Their institution | $12,833 |
| Blueprint Medicines Corporation · 2023 | Their institution | $10,500 |
| NOVARTIS PHARMACEUTICALS CORPORATION · Research Related Publications Support · 2019 | This clinician | $9,425 |
| Novartis Pharmaceuticals Corporation · Phase II Trial of Ceritinib in Combination With Stereotactic Ablative Radiation Sabr in Alk Rearranged Metastatic Lung Adenocarcinoma · 2024 | Their institution | $9,317 |
| Mirati Therapeutics, Inc. · A Phase 1/2 Study of Avutometinib (Vs-6766) in Combination With Adagrasib in Patients With Kras G12c Mutant Non-Small Cell Lung Cancer (Nsclc) (Ramp 204) · 2024 | Their institution | $7,744 |
| Incyte Corporation · An Open Label Phase 1/2 Study of Incb039110 in Combination With Osimertinib in Subjects With Locally Advanced Or Metastatic Non Small Cell Lung Cancer · 2020 | Their institution | $6,810 |
| Incyte Corporation · An Open Label Phase 1/2 Study of Incb039110 in Combination With Osimertinib in Subjects With Locally Advanced Or Metastatic Non Small Cell Lung Cancer · 2024 | Their institution | $6,525 |
| Genentech, Inc. · 2024 | Their institution | $6,250 |
| AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Controlled, Multi-Centre Study of Neoadjuvant Osimertinib As Monotherapy Or in Combination With Chemotherapy Versus Soc Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable, Stages II and Iiia Non-Small Cell Lung Cancer (Neoadaura) · 2025 | Their institution | $4,938 |
| Novartis Pharmaceuticals Corporation · A Phase II Trial To Evaluate Trametinib in Molecular Subpopulation of Patients With Advanced Nonsmalllung Cancer · 2020 | Their institution | $1,966 |
| F. Hoffmann-La Roche AG · Startrk 2 Rxdx 101 02, Alka Alka 372 001 and Startrk 1 Rxdx 101 01 · 2020 | This clinician | $872 |
| F. Hoffmann-La Roche AG · Nautika1 Previously Lcmc4 · 2025 | This clinician | $557 |
| AstraZeneca Pharmaceuticals LP · A Phase III Double-Blind Randomised Placebo-Controlled International Study To Assess the Efficacy and Safety of Adjuvant Osimertinib Versus Placebo in Participants With Egfr Mutation Positive Stage Ia2-Ia3 Non-Small Cell Lung Cancer Following Complete Tumour Resection · 2023 | Their institution | $350 |
| F. Hoffmann-La Roche AG · Open Label Dose Escalation and Expansion Study of Entrectinib Rxdx 101 in Children, Startrk 2 Rxdx 101 02, Alka Alka 372 001 and Startrk 1 Rxdx 101 01 · 2020 | This clinician | $266 |
| F. Hoffmann-La Roche AG · A Phase 11b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib Rxdx-101 in Children and Adolescents With Recurrent Or Refractory Solid Tumors and Primary Cns Tumors, With Or Without Trk, Ros1, Or Alk Fusions, An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced Or Metastatic Solid Tumors That Harbor Ntrk123, Ros1, Or Alk Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib Rxdx-101 in Adult · 2020 | This clinician | $260 |
| Spectrum Pharmaceuticals Inc. · Spi-Poz-202 · 2019 | Their institution | $150 |
| Genentech, Inc. · Startrk 2 Rxdx 101 02 · 2025 | Their institution | $133 |
| E.R. Squibb & Sons, L.L.C. · A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy Vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced Or Metastatic Non-Squamous Non-Small Cell Lung Cancer With Kras G12c Mutation (Krystal-4) · 2025 | Their institution | $89 |
| Genentech, Inc. · Nautika1 Previously Lcmc4 · 2025 | Their institution | $67 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1528287174
- Licence
- CA A106689, PA MT190228California A106689: Current · expires 2028-06-30
- Trained
- Perelman School of Med at the University of Pennsylvania, 2007 · 19 years ago
- Group
- University of California San Francisco · UCSF Medical Group Business Services
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X); Internal medicine (207R00000X)
- Mailing address
- 505 Parnassus Ave, Moffit M1286, San Francisco, CA, 94143
- NPI first listed
- 2007-04-24
- NPI last updated
- 2009-06-16
This is when the NPI record was last certified, not a medical board exam.